파로스아이바이오

388870KOSDAQ

40.1 / 100

Reference Date: 2026-09-08

Financial Score7.5 / 40

News Sentiment16.6 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Slightly down 4.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Paros AI Bio is a R&D-focused company developing innovative drugs for rare and intractable diseases using its AI-based drug discovery platform, Chemiverse. Its lead pipeline, Lasmotinib (PHI-101), is an acute myeloid leukemia treatment designated as an orphan drug in the US, Korea, and Europe. The company also develops PHI-101-OC, a candidate for recurrent ovarian cancer. The platform enables faster drug development with reduced costs and higher success rates.

Number of Employees

33people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.92Industry Average 1.200.0Point

4.1x industry avg (risky)

ROE

-66.12Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

104.48Industry Average 100.002.0Point

Higher than industry avg (caution)

Trend 2023~20251.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

0.0 / 3

Avg ▼7.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -49.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 1Negative 1Average Sentiment Score 66.2

Positive
파로스아이바이오-코오롱제약, EGFR 저해제 공동개발 '맞손'
파로스아이바이오와 코오롱제약의 EGFR 저해제 공동개발 계약 체결로 신약 개발 가속화 기대.
Positive
파로스아이·코오롱제약 "공동연구개발 체제가동"
파로스아이바이오와 코오롱제약의 공동연구개발 계약 확대는 신약 개발에 대한 긍정적 투자 신호를 제공합니다.
Negative
해외선 벌써 3상, 우린 겨우 1상 AI 신약 개발도 ‘부익부 빈익빈’
해외 기업들의 빠른 AI 신약 임상 진행 속도와 대조적으로 국내 파로스아이바이오의 개발 지연이 우려되며, 정부 지원과 협력 생태계의 필요성이 강조됨.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 5,290Won52-week high 11,62052-week low 4,310

1-month return2.0Point

1m -3.99% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-13